keyword
MENU ▼
Read by QxMD icon Read
search

diagnosis of prostate cancer

keyword
https://www.readbyqxmd.com/read/28820986/an-ultrasensitive-sandwich-type-electrochemical-immunosensor-based-on-the-signal-amplification-strategy-of-echinoidea-shaped-au-ag-cu2o-nanoparticles-for-prostate-specific-antigen-detection
#1
Yuying Yang, Qin Yan, Qing Liu, Yongpeng Li, Hui Liu, Ping Wang, Lei Chen, Daopeng Zhang, Yueyun Li, Yunhui Dong
Highly sensitive determination of tumor markers plays an important role in early diagnosis of cancer. Herein, a novel and ultrasensitive sandwich-type electrochemical immunosensor was fabricated for quantitative detection of prostate specific antigen (PSA). In this process, gold nanoparticles functionalized nitrogen-doped graphene quantum dots (Au@N-GQDs) was synthesized through a simple and green hydrothermal procedure to enhance conductivity, specific electrode surface area and quantity of immobilized primary antibodies (Ab1)...
August 10, 2017: Biosensors & Bioelectronics
https://www.readbyqxmd.com/read/28820285/oligometastatic-cancer-stereotactic-ablative-radiotherapy-for-patients-affected-by-isolated-body-metastasis
#2
Andrea Lancia, Gianluca Ingrosso, Alessandra Carosi, Luana Di Murro, Emilia Giudice, Sara Cicchetti, Pasquale Morelli, Daniela di Cristino, Claudia Bruni, Alessandra Murgia, Alessandro Cancelli, Irene Turturici, Anjali Iadevaia, Elisabetta Ponti, Riccardo Santoni
BACKGROUND: To evaluate the outcome of patients affected by a single isolated body metastasis treated with stereotactic body radiotherapy (SBRT). MATERIAL AND METHODS: Seven-eight patients were treated with SBRT for isolated body metastasis. The most frequent primary tumor was prostate cancer (28.2%), followed by colorectal cancer (23.1%) and lung cancer (20.5%). Median age at diagnosis of oligometastatic disease was 70 years (range 47-88). Median Karnofsky Performance Status (KPS) was 90 (range 70-100)...
August 18, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28819434/identification-of-transcription-factor-yy1-as-a-regulator-of-a-prostate-cancer-specific-pathway-using-proteomic-analysis
#3
Arum Park, Jiyeong Lee, Sora Mun, Doo Jin Kim, Byung Heun Cha, Kyong Tae Moon, Tag Keun Yoo, Hee-Gyoo Kang
Prostate-specific antigen, a biomarker used to diagnose prostate cancer, exhibits poor sensitivity. Although previous studies have focused on identifying a new diagnostic biomarker, the molecules or networks identified in these studies are also present in other cancers, making it difficult to detect prostate cancer specifically. A unique characteristic of the prostate gland is the increased mitochondrial energy metabolism when normal prostate cells progress to cancer cells. Thus, we attempted to find a prostate cancer-specific signature present in this unique environment...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28818491/cryotherapy-versus-high-intensity-focused-ultrasound-for-treating-prostate-cancer-oncological-and-functional-results
#4
F Donis Canet, M D Sánchez Gallego, F Arias Fúnez, G Duque Ruíz, I Laso, J Brasero Burgos, J Lorca Álvaro, V Gómez Dos Santos, R Rodríguez Patrón, F J Burgos Revilla
CONTEXT AND OBJECTIVE: The increasingly early diagnosis of prostate cancer requires a search for therapeutic alternatives with good oncological results that in turn facilitate a good long-term quality of life. This review analyses 2 minimally invasive therapies for treating localised prostate cancer in terms of oncological and functional results, as well as the complications resulting from the therapies. ACQUISITION OF EVIDENCE: A systematic literature review was conducted of the treatment of localised prostate cancer with 2 ablative techniques as the primary therapy: cryosurgery or cryotherapy and high intensity focused ultrasound (HIFU)...
August 14, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28818202/risk-of-arterial-thromboembolism-in-patients%C3%A2-with%C3%A2-cancer
#5
Babak B Navi, Anne S Reiner, Hooman Kamel, Costantino Iadecola, Peter M Okin, Mitchell S V Elkind, Katherine S Panageas, Lisa M DeAngelis
BACKGROUND: The risk of arterial thromboembolism in patients with cancer is incompletely understood. OBJECTIVES: The authors aimed to better define this epidemiological relationship, including the effects of cancer stage. METHODS: Using the Surveillance Epidemiology and End Results-Medicare linked database, the authors identified patients with a new primary diagnosis of breast, lung, prostate, colorectal, bladder, pancreatic, or gastric cancer or non-Hodgkin lymphoma from 2002 to 2011...
August 22, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28817656/investigation-of-the-halo-artifact-in-68ga-psma-11-pet-mri
#6
Thorsten Heußer, Philipp Mann, Christopher M Rank, Martin Schäfer, Antonia Dimitrakopoulou-Strauss, Heinz-Peter Schlemmer, Boris A Hadaschik, Klaus Kopka, Peter Bachert, Marc Kachelrieß, Martin T Freitag
OBJECTIVES: Combined positron emission tomography (PET) and magnetic resonance imaging (MRI) targeting the prostate-specific membrane antigen (PSMA) with a 68Ga-labelled PSMA-analog (68Ga-PSMA-11) is discussed as a promising diagnostic method for patients with suspicion or history of prostate cancer. One potential drawback of this method are severe photopenic (halo-) artifacts surrounding the bladder and the kidneys in the scatter-corrected PET images, which have been reported to occur frequently in clinical practice...
2017: PloS One
https://www.readbyqxmd.com/read/28816284/-predictive-factor-analysis-of-time-to-progression-of-castration-resistant-prostate-cancer-after-androgen-deprivation-therapy
#7
G J Ji, C Huang, G Song, X S Li, Y Song, L Q Zhou
OBJECTIVE: To explore risk factors including prostate-specific antigen (PSA) kinetics for the prediction of castration-resistant prostate cancer (CRPC), and to build a practical model for predicting the progression to CRPC after androgen deprivation therapy (ADT) so as to facilitate clinicians in decision-making for prostate cancer patients receiving ADT. METHODS: A total of 185 patients with prostate cancer who had received ADT as the primary therapy in Department of Urology of Peking University First Hospital from 2003 to 2014 were enrolled retrospectively...
August 18, 2017: Beijing da Xue Xue Bao. Yi Xue Ban, Journal of Peking University. Health Sciences
https://www.readbyqxmd.com/read/28815924/urinary-micrornas-for-prostate-cancer-diagnosis-prognosis-and-treatment-response-are-we-there-yet
#8
REVIEW
Ovidiu Balacescu, Bogdan Petrut, Oana Tudoran, Dragos Feflea, Loredana Balacescu, Andrei Anghel, Ioan O Sirbu, Edward Seclaman, Catalin Marian
Prostate cancer (PCa) remains one of the leading causes of cancer-related deaths in men. Despite the tremendous progress in research over the years, a suitable minimally invasive PCa biomarker is yet to be discovered. The recent advances regarding the roles of microRNAs as biomarkers has allowed for their study in PCa as well, especially as blood-based markers. However, there are several studies that used urine as biological sample to evaluate microRNAs as biomarkers for PCa diagnosis, prognosis, and treatment response, which were reviewed herein...
August 16, 2017: Wiley Interdisciplinary Reviews. RNA
https://www.readbyqxmd.com/read/28815472/comparison-of-pet-ct-and-whole-mount-histopathology-sections-of-the-human-prostate-a-new-strategy-for-voxel-wise-evaluation
#9
F Schiller, T Fechter, C Zamboglou, A Chirindel, N Salman, C A Jilg, V Drendel, M Werner, P T Meyer, A-L Grosu, M Mix
BACKGROUND: Implementation of PET/CT in diagnosis of primary prostate cancer (PCa) requires a profound knowledge about the tracer, preferably from a quantitative evaluation. Direct visual comparison of PET/CT slices to whole prostate sections is hampered by considerable uncertainties from imperfect coregistration and fundamentally different image modalities. In the current study, we present a novel method for advanced voxel-wise comparison of histopathology from excised prostates to pre-surgical PET...
August 17, 2017: EJNMMI Physics
https://www.readbyqxmd.com/read/28814879/circulating-tumor-cells-correlate-with-patterns-of-recurrence-in-patients-with-hormone-sensitive-prostate-cancer
#10
Giandomenico Roviello, Silvia Paola Corona, Alberto Bonetta, Maria Rosa Cappelletti, Daniele Generali
The aim of this study was to evaluate the correlation between circulating tumor cells (CTCs) and patterns of recurrence in patients with hormone-sensitive prostate cancer. The study involved patients with histologically confirmed, advanced prostatic adenocarcinoma, who were tested for CTCs (Veridex(®)) when they developed recurrence after radical prostatectomy or external beam radiation between 2008 and 2014. Forty-two prostate cancer patients were evaluated. CTCs were detected in 14 out of 42 (33.3%) patients (Group A), while the remaining 28 (66...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28814708/-a-case-of-pulmonary-tumor-thrombotic-microangiopathy-in-castration-resistant-prostate-cancer
#11
Kodai Hattahara, Akihiro Hamada, Rie Oyama, Kimihiko Masui, Yasumasa Shichiri
A man aged 83 years under treatment with enzalutamide for castration-resistant prostate cancer presented with general malaise and exertional dyspnea. The underlying cause could not be identified by further investigations. On the 5th hospital day, he died due to a sudden exacerbation of dyspnea. The results of an autopsy indicated tumor emboli and stenosis of small pulmonary arteries with the fibrocellular intimal thickening, and therefore our final diagnosis was pulmonary tumor thrombotic microangiopathy.
July 2017: Hinyokika Kiyo. Acta Urologica Japonica
https://www.readbyqxmd.com/read/28814252/bone-imaging-in-metastatic-castration-resistant-prostate-cancer-where-do-we-stand
#12
Petros Sountoulides, Linda Metaxa
We are witnessing an era of increased clinical interest in metastatic castration-resistant prostate cancer, both in terms of treatment and also in terms of imaging options. This surge in interest is attributed to the recent developments in treatments for metastatic prostate cancer that are able to confer a significant survival advantage. We are therefore anticipating an increase in the number of patients that we will need to treat at this disease stage. Imaging is undoubtedly crucial in monitoring disease response to treatment and progression...
August 16, 2017: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/28813783/comprehensive-overview-of-prostatitis
#13
REVIEW
Farhan Ullah Khan, Awais Ullah Ihsan, Hidayat Ullah Khan, Ruby Jana, Junaid Wazir, Puregmaa Khongorzul, Muhammad Waqar, Xiaohui Zhou
Prostatitis is a common urinary tract syndrome that many doctors find problematic to treat effectively. It is the third most commonly found urinary tract disease in men after prostate cancer and Benign Prostate Hyperplasia (BPH). Prostatitis may account for 25% of all office visits made to the urological clinics complaining about the genital and urinary systems all over the world. In the present study, we classified prostatitis and comprehensively elaborated the etiology, pathogenesis, diagnosis, and treatment of acute bacterial prostatitis (category I), chronic bacterial prostatitis (category II), chronic pelvic pain syndrome (CPPS) (category III), and asymptomatic prostatitis (category IV)...
August 12, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28813230/dietary-supplements-commonly-used-by-cancer-survivors-are-there-any-benefits
#14
Mary J Marian
Following a cancer diagnosis, dietary supplements are reportedly used by 20%-80% of individuals. Supplements are most commonly used by breast cancer survivors, followed by patients with prostate, colorectal, and lung cancers, which is not surprising since these are the most common types of cancer diagnosed in adults. Reasons cited for such use include improving quality of life, reducing symptoms related to treatment and/or the disease process, and recommendation from medical practitioners; family and friends may also be an influence...
August 1, 2017: Nutrition in Clinical Practice
https://www.readbyqxmd.com/read/28813037/concomitant-bladder-cancer-and-prostate-cancer-challenges-and-controversies
#15
REVIEW
Antonio Lopez-Beltran, Liang Cheng, Francesco Montorsi, Maria Scarpelli, Maria R Raspollini, Rodolfo Montironi
Radical cystoprostatectomy (RCP) followed by bilateral pelvic lymphadenectomy and urinary diversion remains the gold-standard therapy for men with localized muscle-invasive bladder cancer (MIBC). Prostate cancer might be incidentally detected at the time of RCP with a reported prevalence of 24-51%. Typically, these patients are considered to have clinically insignificant disease, but data from emerging series challenge this assumption and suggest that some of these tumours might be aggressive, or somehow increase the aggressiveness of the associated MIBC, and can negatively influence the patient's overall survival outcomes...
August 16, 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/28812325/ambiguity-in-a-masculine-world-being-a-brca1-2-mutation-carrier-and-a-man-with-prostate-cancer
#16
C Moynihan, E K Bancroft, A Mitra, A Ardern-Jones, E Castro, E C Page, R A Eeles
BACKGROUND: Increased risk of prostate cancer(PCa) is observed in men with BRCA1/BRCA2 mutations. Sex and gender are key determinants of health and disease although unequal care exists between the sexes. Stereotypical male attitudes are shown to lead to poor health outcomes. METHODS: Men with BRCA1/2 mutations and diagnosed with PCa were identified and invited to participate in a qualitative interview study. Data were analysed using a Framework approach. 'Masculinity theory' was used to report the impact of having both a BRCA1/2 mutation and PCa...
August 15, 2017: Psycho-oncology
https://www.readbyqxmd.com/read/28810986/cancer-incidence-among-patients-of-the-u-s-veterans-affairs-health-care-system-2010-update
#17
Leah L Zullig, Kellie J Sims, Rebecca McNeil, Christina D Williams, George L Jackson, Dawn Provenzale, Michael J Kelley
INTRODUCTION: Nearly 50,000 incident cancer cases are reported in Veterans Affairs (VA) Central Cancer Registry (VACCR) annually. This article provides an updated report of cancer incidence recorded in VACCR. MATERIALS AND METHODS: Data were obtained from VACCR for incident cancers diagnosed in the VA health care system, focusing on 2010 data. Cancer incidence among VA patients is described by anatomical site, sex, race, stage, and geographic location, and was compared to the general U...
July 2017: Military Medicine
https://www.readbyqxmd.com/read/28810879/quantification-of-mutant-spop-proteins-in-prostate-cancer-using-mass-spectrometry-based-targeted-proteomics
#18
Hui Wang, Christopher E Barbieri, Jintang He, Yuqian Gao, Tujin Shi, Chaochao Wu, Athena A Schepmoes, Thomas L Fillmore, Sung-Suk Chae, Dennis Huang, Juan Miguel Mosquera, Wei-Jun Qian, Richard D Smith, Sudhir Srivastava, Jacob Kagan, David G Camp, Karin D Rodland, Mark A Rubin, Tao Liu
BACKGROUND: Speckle-type POZ protein (SPOP) is an E3 ubiquitin ligase adaptor protein that functions as a potential tumor suppressor, and SPOP mutations have been identified in ~10% of human prostate cancers. However, it remains unclear if mutant SPOP proteins can be utilized as biomarkers for early detection, diagnosis, prognosis or targeted therapy of prostate cancer. Moreover, the SPOP mutation sites are distributed in a relatively short region with multiple lysine residues, posing significant challenges for bottom-up proteomics analysis of the SPOP mutations...
August 15, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/28808871/african-american-prostate-cancer-disparities
#19
REVIEW
Zachary L Smith, Scott E Eggener, Adam B Murphy
PURPOSE OF REVIEW: The purpose of this review is to examine prostate cancer racial disparities specific to the African-American population. RECENT FINDINGS: African-American men are more likely to be diagnosed with prostate cancer, present at an earlier age; are more likely to have locally advanced or metastatic disease at diagnosis; and have suboptimal outcomes to standard treatments. Prostate cancer treatment requires a nuanced approach, particularly when applying screening, counseling, and management of African-American men...
August 14, 2017: Current Urology Reports
https://www.readbyqxmd.com/read/28808670/utilization-and-predictors-of-expectant-management-among-elderly-men-with-low-and-intermediate-risk-localized-prostate-cancer-in-u-s-urological-practice
#20
Huei-Ting Tsai, George Philips, Kathryn L Taylor, Keith Kowalczyk, Kuo Huai-Ching, Arnold L Potosky
INTRODUCTION: Expectant management (EM) reduces overtreatment in low-risk but not intermediate-risk localized prostate cancer (PCa). We assessed the use and predictors of EM to understand its uptake in U.S. practice. METHODS: Using the U.S. SEER-Medicare database, we conducted a retrospective cohort study of men 66 years and older diagnosed with low-risk (N=25,506) or intermediate-risk (N=25,597) localized PCa between 2004 - 2011 and followed through December 31, 2012...
March 2017: Urology Practice
keyword
keyword
75198
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"